| __timestamp | Apellis Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 34916000 |
| Thursday, January 1, 2015 | 6356782 | 36949000 |
| Friday, January 1, 2016 | 4303743 | 45240000 |
| Sunday, January 1, 2017 | 10463151 | 62416000 |
| Monday, January 1, 2018 | 22639184 | 81289000 |
| Tuesday, January 1, 2019 | 67046483 | 100359000 |
| Wednesday, January 1, 2020 | 139401000 | 105326000 |
| Friday, January 1, 2021 | 176771000 | 122356000 |
| Saturday, January 1, 2022 | 277163000 | 152848000 |
| Sunday, January 1, 2023 | 500815000 | 184259000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, Corcept Therapeutics Incorporated and Apellis Pharmaceuticals, Inc. have taken different paths in managing these costs. From 2014 to 2023, Corcept has shown a more consistent approach, with SG&A expenses growing by approximately 428%, from $34.9 million to $184.3 million. In contrast, Apellis has experienced a staggering increase of over 17,000%, from $2.9 million to $500.8 million.
While both companies have seen their SG&A expenses rise, Corcept's steadier growth suggests a more controlled cost management strategy. This could be indicative of a more mature operational model, whereas Apellis's rapid increase might reflect aggressive expansion efforts. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights